The infusion therapy landscape is set to embark on another year of regulatory change, as 2026 promises to be shaped by updated CMS reimbursement rules and tighter oversight of drug pricing. Historically, the economics of infusion centers rely heavily on predictable reimbursement linked to drug cost, administration time, and supportive clinical services.
Therefore, adherence to ASP and transparency in the revenue cycle will be vital to securing income stability, and understanding how the 2026 CMS Fee Schedule Policy will fit into your billing process will reduce payment lapses and mitigate audit risk.
Strong Emphasis on Compliance with ASP in Billing
In 2026, CMS will continue to refine the processes of collecting, auditing, and adjusting ASP data. Any discrepancies in the collection and billing of any of these medications will result in delayed claims or even retrospective adjustments. It is critical to have the best record-keeping of drug acquisition prices and to collect accurate ASP prices through claims.
CMS also intends to further scrutinize biosimilars and new-to-market infusion drugs. For infusion centers, this translates into validating the correct HCPCS code, dosing unit, and billing modifier each and every time there is a product update on the quarterly pricing file. As scrutiny for waste billing and unit calculations further heightens, accuracy has never been more critical.
Increased Focus on Documentation to Justify High-Cost Drugs
Infusion drugs, including biologics, monoclonal antibodies, and complex oncology agents, are extremely expensive. In the near term, payers will continue to demand strong evidence of medical necessity prior to approval or reimbursement of these treatments. For 2026, documentation should clearly connect diagnosis, response to prior treatment, and clinical guidelines to the selected drug regimen.
Delays, partial payments, and denials can result from missing information. Instituting a standard documentation process for all categories of infusion will minimize rework and ensure predictable cash flow.
Prior Authorization May Slow Revenue Without Strong Processes
While the 2026 rule brings about a change in telehealth and practice expense structure, prior authorization remains one of the biggest bottlenecks for infusion centers. Most medications have renewed authorizations tied to dosing cycles or response updates. The small delay in approval disrupts patient scheduling and revenue forecasting.
Infusion centers must develop proactive tracking systems for authorization, including renewal reminders, clinical checklists, and protocols for direct communications with payers. Tying authorization status with scheduling software prevents the administration before approval, usually outright non-payment.
Revenue Cycle Strategies for a More Stable 2026
This requires strong revenue cycle management to maintain profitability in light of the evolving CMS rules. Specifically:
- Regular internal audits of ASP pricing updates
- Monthly review of infusion CPT and HCPCS changes
- Clear workflows for new biologic and biosimilar launches
- Better coordination between the pharmacy, nursing, and billing teams.
- Analytics to identify Recurring Denial Patterns
- Tight reconciliations between drug inventory and claim submissions
Infusion centers that modernize their RCM processes will see fewer denials and faster turnaround times.
Why Many Providers Choose to Outsource Their Infusion Center Billing
Increasing complexity in drug pricing, ASP variations, and prior authorizations has led many infusion centers to outsource infusion center billing to specialist teams such as RCM Workshop. Outsourcing confers the following advantages:
- Real-time compliance monitoring
- Clean claim submission tied to ASP updates
- Reduced administrative burden on clinical staff
- Strong denial management
- Better forecasting through data-driven reporting
Partnering with a dedicated team like RCM Workshop for revenue cycle management helps your infusion center billing stay focused on patient care with strong revenue, with no compromises.
